SEC For	m 4																		
FORM 4 UNITED ST				STATE	TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERS									IP OMB Number: 3235-0 Estimated average burden hours per response:			3235-0287 0.5		
Instruc	tion 1(b).			Filed p	or Sec	t to Sectio tion 30(h)	n 16(of the	a) of the Sec Investment	urities Exc Company J	hange Act of 1	Act of 1 1940	934		<u> </u>					
1. Name and Address of Reporting Person [*] <u>Kim Anthony H.</u>					2. Issuer Name and Ticker or Trading Symbol <u>Marker Therapeutics, Inc.</u> [MRKR]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				ner		
(Last) C/O MA	(Last) (First) (Middle) C/O MARKER THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 02/17/2022								X Officer (give title Other (speci below) below) Chief Financial Officer						
3200 SOUTHWEST FREEWAY, SUITE 2500				4	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) HOUSTON TX													X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																			
		Та	ble I - Non-l	Derivati	ive Se	ecuritie	s Ac	quired, D	ispose	d of, d	or Bei	neficially	owned						
Date				. Transacti Date Month/Day	Execution			Transaction Dispo Code (Instr.			ırities Acquired (A) ed Of (D) (Instr. 3, 4		and 5) Securities Beneficial Owned Fo		Form	Direct Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code \	/ Amou	int	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)				
			Table II - De	erivativ .g., put	e Sec s, cal	curities Ils, warr	Acq ants	uired, Dis s, options	sposed , conve	of, or rtible	r Bene e secu	eficially (irities)	Owned		,				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/	ate	of Securities		es g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	re es ally g d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiratio Date	on Tit	tle	Amount or Number of Shares		(Instr. 4)	lion(3)				
Employee Stock Option (right to buy)	\$0.46	02/17/2022		A		160,000		(1)	02/17/20		ommon Stock	160,000	\$0.00	160,0	000	D			

Explanation of Responses:

1. This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. **Remarks:**

/s/ Michael Loiacono, Attorney-02/22/2022

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.